EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Methotrexate for Osteoarthritis: What Does the Evidence Say?

Marina De Castro Fidalgo E Costa, Frederique Ponchel, Kierran Flack, Philip G Conaghan, Sarah R Kingsbury iD

Drugs & Aging · 2026

DOI: 10.1007/s40266-025-01276-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs & Aging, 2026. Verfasst von Marina De Castro Fidalgo E Costa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, …. Hauptthemen laut MEDLINE: Methotrexate, Osteoarthritis, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a leading cause of disability worldwide, characterised by chronic pain and reduced quality of life. Despite its prevalence, pharmacotherapy options remain limited. Inflammation has emerged as a promising target, with anti-inflammatory agents used in other rheumatological conditions, such as methotrexate (MTX), being explored for OA treatment. MTX is a cornerstone therapy in rheumatoid arthritis (RA), owing to its broad immunomodulatory properties and well-established clinical efficacy. This review summarises evidence from seven randomised controlled trials and two observational studies investigating MTX in knee and hand OA. Studies varied considerably in terms of sample size, study population, MTX dosage and follow-up duration. Overall, study outcomes were conflicting in terms of MTX effect on OA symptoms. However, trials with larger sample sizes and higher MTX doses (> 15 mg/week) consistently reported benefits for pain in knee and hand OA, with a favourable safety profile, supporting MTX as a potential OA treatment. There is still a need for further research to refine dosing strategies, assess longer term use and evaluate cost-effectiveness. Given the complex heterogeneity of OA, stratification by OA phenotype, particularly consideration of local and systemic inflammation, may also be important to underpin selection of a population most likely to respond to MTX treatment. Considerations for the use of MTX in older adults, where comorbidities and polypharmacy may impact use, will also be essential for clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateOsteoarthritisAntirheumatic AgentsHumansRandomized Controlled Trials as Topic

Substanzen

MethotrexateAntirheumatic Agents

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK.
  • National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. s.r.kingsbury@leeds.ac.uk.
  • National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. s.r.kingsbury@leeds.ac.uk.

ORCID-Profile: Sarah R Kingsbury

Zitieren

APA

De Castro Fidalgo E Costa, M., Ponchel, F., Flack, K., Conaghan, P. G., & Kingsbury, S. R. (2026). Methotrexate for Osteoarthritis: What Does the Evidence Say?. Drugs & Aging. https://doi.org/10.1007/s40266-025-01276-4

Vancouver

De Castro Fidalgo E Costa M, Ponchel F, Flack K, Conaghan PG, Kingsbury SR. Methotrexate for Osteoarthritis: What Does the Evidence Say?. Drugs & Aging. 2026. doi:10.1007/s40266-025-01276-4

BibTeX
@article{DeCastroFidalgoECosta2026,
  author = {De Castro Fidalgo E Costa, Marina and Ponchel, Frederique and Flack, Kierran and Conaghan, Philip G and Kingsbury, Sarah R},
  title = {Methotrexate for Osteoarthritis: What Does the Evidence Say?},
  journal = {Drugs & Aging},
  year = {2026},
  doi = {10.1007/s40266-025-01276-4}
}
Kostenlos starten →